Samsung Biologics said it has signed a contract with an Asian-based pharmaceutical company to produce 1.7 trillion won worth of medicines.
This is nearly half of last year's total orders, and Samsung Biologics' cumulative orders this year, including this contract, exceeded 4 trillion won for the first time ever.
Samsung Biologics said it has secured 17 of the world's top 20 pharmaceutical companies as customers, and explained that it will secure 784,000 liters of drug production capacity when the 5th plant in Songdo, Incheon is completed in April next year.
※ 'Your report becomes news'
[Kakao Talk] YTN Search and Add Channel
[Phone] 02-398-8585
[Mail] social@ytn.co.kr
[Copyright holder (c) YTN Unauthorized reproduction, redistribution and use of AI data prohibited]
Economy
View the full list of articles- "Retirement is an old saying".Those over 60 years old are the first to be in their 50s.
- 50,000 Electronics' 52-week low again... 2.2% ↓ 57,700 won fall
- 8th Meeting of the Delivery Platform-Building Company Win-Win Council...Should we come up with a win-win plan?
- The won-dollar exchange rate rose to 1,380 won...Best since the end of July